Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acambis submits smallpox vaccine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Acambis completes rolling BLA submission for its ACAM2000 smallpox vaccine, the firm says April 18. Assuming a priority review and mid-April submission, the vaccine has a mid-October PDUFA date. Acambis initiated the rolling submission in February (1Pharmaceutical Approvals Monthly February 2006, In Brief). The firm received a $428 mil. U.S. government grant in 2001 for production of the vaccine...

You may also be interested in...



Acambis smallpox vaccine rolling BLA

Acambis has initiated a rolling BLA for its cell culture-based smallpox vaccine ACAM2000, with plans to complete the submission this April, the firm announces Jan. 18. Based on the vaccine's fast-track status, Acambis hopes to receive a decision "before the end of the year." Acambis received an HHS grant worth $428 mil. in 2001 to produce 155 mil. doses of the vaccine; the firm said it has delivered 182.5 mil. doses to the U.S. government for stockpiling. The firm's clinical program included 3,800 subjects...

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Six Questions For Sun Pharma MD Shanghvi

Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel